Current Report Filing (8-k)
November 07 2017 - 5:24PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 2, 2017
JUNIPER PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-10352
|
|
59-2758596
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
33 Arch Street
Suite 3110
Boston,
Massachusetts
|
|
02110
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
639-1500
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 or Rule
12b-2
of the Securities Exchange Act of 1934.
Emerging
Growth Company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition
period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operation and Financial Condition
On November 2, 2017, Juniper Pharmaceuticals, Inc. (the Company), issued a press release announcing the financial results for the three-month
period ended September 30, 2017, entitled Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results (the Press Release). A copy of the Press Release is furnished as Exhibit 99.1 hereto.
Also on November 2, 2017, following the issuance of the press release referred to above, the Company conducted a conference call to discuss the reported
operating and financial results. A copy of the script of the conference call is furnished herewith as Exhibit 99.2.
The information contained in this
Item 2.02 of the Current Report on Form
8-K
and Exhibits 99.1 and 99.2, shall not be deemed filed for the purposes of Section 18 of the United State Securities Exchange Act of 1934, as amended, or
otherwise subject to the liability of Section 18. Furthermore, such information shall not be deemed incorporated by reference into any registration statement or any other filing under the United States Securities Act of 1933, as amended, except
as shall be expressly set forth by specific references in such filings.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
JUNIPER PHARMACEUTICALS, INC.
|
|
|
By:
|
|
/s/ Jeffrey E. Young
|
Name:
Title:
|
|
Jeffrey E. Young
Senior Vice President,
Finance, Chief Financial Officer and Treasurer
|
Date: November 7, 2017
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release dated November 2, 2017, entitled Juniper Pharmaceuticals Reports Third Quarter 2017 Financial and Operating Results, furnished herewith.
|
|
|
99.2
|
|
Script of the Juniper Pharmaceuticals Q3 2017 Financial Results Call.
|
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Juniper Pharmaceuticals, Inc. (NASDAQ:JNP)
Historical Stock Chart
From Sep 2023 to Sep 2024